Vital Science

Vital Science comes at drug development from two directions: the families who need new treatments and the scientists trying to build them. The titles lead with a name, be it a foundation, a company, a therapy or a gene, as in 'Cure EB: Healing the Wounds', 'Mission Therapeutics: Inhibiting DUBs to Halt Diseases' and 'H-Guard: Improving Physical and Mental Health'. The foundation episodes are more than testimony. In 'FOXG1: A Mom’s Mission', a speaker argues that patient foundations are best placed to drive preclinical development because the work is 'not just a job' for them. The same conversation turns technical quickly. FOXG1 is described as a single-exon gene small enough for a viral vector, gene replacement leads ahead of ASO and small-molecule platforms, and animal models are said to show full rescue of the corpus callosum, an outcome pharmaceutical companies had told the speaker was out of reach. The Cure EB episode is harder listening. Epidermolysis bullosa is compared to being flayed alive, and a parent recounts a child who improved on a trial, saw no real follow-on, worked with a psychologist toward accepting the condition, and found university hard at first without her mother doing the dressings. 'Cure Rare Disease: Continuing a Legacy' remembers Terry, whose part in the research is described as undertaken for younger patients with ultra-rare disease, many of whom are kept out of trials by age or ambulation status. The company episodes trade testimony for mechanism. Clear Scientific argues that methamphetamine use is the fastest-growing form of drug abuse, that it has no treatment, and that most people use more than one drug at a time, deliberately or not. Its answer is an acyclic molecule shaped like the letter C, likened to Pac-Man swallowing a pellet and given by intravenous, intramuscular or subcutaneous injection. In the Mission Therapeutics episode, a speaker sees Parkinson's care moving past dopamine replacement toward disease modification, and narration sets out the company's approach: molecules that form strong but reversible bonds at the catalytic site of DUBs. In the H-Guard episode, a speaker recalls tiring of promises made in academic writing and taking research toward the clinic, into dialysis care, where innovation has, in the speaker's words, kind of stalled. The episodes are built on interviews, and the Mission Therapeutics one adds narration to carry the chemistry between answers. Promos in the feed point to a limited series, 'Bold New Approaches', on NAMs, alternative methods and regulation. They also point to Eureka's Sounds of Science, which a promo voiced by Mary Parker says Vital Science will fold into. A good first episode is 'FOXG1: A Mom’s Mission', which carries both halves of the show in one conversation: a foundation's urgency alongside a gene therapy's details. 'Clear Scientific: Combatting Drug Overdose from Methamphetamine, Fentanyl, and Polydrug' then shows how the company episodes make chemistry concrete.